Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Spesolimab (Primary)
- Indications Palmoplantar pustulosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 15 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 Sep 2018 This trial has been Completed in Spain.
- 17 Jul 2018 According to EudraCT record, this trial has been completed in Denmark.